Raymond James Financial Inc. Purchases Shares of 73,510 REGENXBIO Inc. (NASDAQ:RGNX)

Raymond James Financial Inc. bought a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 73,510 shares of the biotechnology company's stock, valued at approximately $568,000. Raymond James Financial Inc. owned 0.15% of REGENXBIO at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in REGENXBIO by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company's stock valued at $11,422,000 after purchasing an additional 44,037 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after acquiring an additional 296,700 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock worth $4,382,000 after acquiring an additional 37,055 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in REGENXBIO by 8.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company's stock valued at $1,273,000 after purchasing an additional 13,014 shares during the period. Finally, Stifel Financial Corp grew its holdings in shares of REGENXBIO by 13.3% during the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock worth $1,566,000 after purchasing an additional 17,563 shares during the period. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RGNX. The Goldman Sachs Group lowered shares of REGENXBIO from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $38.00 to $14.00 in a report on Tuesday, February 11th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. HC Wainwright cut their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Morgan Stanley raised their price target on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $32.78.

REGENXBIO Price Performance

Shares of RGNX stock traded up $0.48 during trading hours on Friday, reaching $5.89. 1,224,210 shares of the stock were exchanged, compared to its average volume of 792,769. The business's fifty day moving average is $7.00 and its two-hundred day moving average is $8.29. The firm has a market capitalization of $295.19 million, a P/E ratio of -1.17 and a beta of 1.26. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $19.38.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. The company had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, equities research analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.